首页 | 本学科首页   官方微博 | 高级检索  
     


Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients
Authors:Cedric Hirzel  Arnaud G. L'Huillier  Victor H. Ferreira  Tina Marinelli  Terrance Ku  Matthew Ierullo  Congrong Miao  D. Scott Schmid  Stephen Juvet  Atul Humar  Deepali Kumar
Affiliation:1. Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada;2. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA;3. Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
Abstract:
Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years). We enrolled 50 patients of which 49 received at least one vaccine dose. Anti-glycoprotein E (gE) antibody levels (n = 43) increased significantly compared to baseline (median optical density [OD] 1.96; interquartile range [IQR]: 1.17–2.89) after the first (median OD 3.41, IQR 2.54–3.81, p < .0001) and second vaccine dose (median OD 3.63, IQR 3.39–3.86, p < .0001). gE-specific polyfunctional CD4+ T cell frequencies (n = 38) also increased from baseline (median 85 per 106 CD4+ T cells; IQR: 46–180) to the first (median 128 per 106 CD4+ T cells; IQR: 82–353; p = .023) and after the second dose (median 361 per 106 CD4+ T cells; IQR: 146–848; p < .0001). Tenderness (83.0%; 95%CI: 69.2–92.4%) and redness (31.9%; 95%CI: 19.1–47.1%) at injection site were common. One rejection episode within 3 weeks of vaccination was observed. This is the first study demonstrating that RZV was safe and elicited significant humoral and cell-mediated immunity in lung transplant recipients. RZV is a new option for the prevention of shingles in this population.
Keywords:clinical research/practice  complication: infectious  infection and infectious agents - viral  vaccine  lung transplantation/pulmonology  translational research/ science  infectious disease
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号